On a standalone basis, Astrazeneca Pharma India's net profit dropped 8.2% to Rs 26.70 crore in Q3 December 2019 as against Rs 29.09 crore reported in Q3 December 2018.
Net sales rose 4% to Rs 223.86 crore in Q3 December 2019 over Q3 December 2018. The result was announced after market hours yesterday, Monday, 3 February 2020.
Standalone profit before tax (PBT) fell 13.3% to Rs 35.18 crore in Q3 December 2019 as compared to Rs 40.59 crore posted in Q3 December 2018.
Shares of Astrazeneca Pharma fell 1.67% to Rs 2,567.35. The stock traded in the range of Rs 2,631.40 to Rs 2,545.40.
AstraZeneca Pharma India is engaged in the discovery, development and commercialization of medicines for core areas of healthcare, including cardiovascular/metabolic disease, cancer and respiratory, inflammatory and autoimmune disease. The company operates through two segments: healthcare and clinical trial.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
